The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study
Background & Aims: Data on the economic and humanistic burden of non-alcoholic steatohepatitis (NASH) are scarce. This study assessed the comparative burden of NASH, relative to a representative sample from the general population and a type 2 diabetes mellitus (T2DM) cohort, in terms of health-r...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-09-01
|
| Series: | JHEP Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555919300576 |
| _version_ | 1811270098851201024 |
|---|---|
| author | Maria-Magdalena Balp Nancy Krieger Raymond Przybysz Nate Way Jennifer Cai Dion Zappe Sarah Jane McKenna Garth Wall Nico Janssens Elliot Tapper |
| author_facet | Maria-Magdalena Balp Nancy Krieger Raymond Przybysz Nate Way Jennifer Cai Dion Zappe Sarah Jane McKenna Garth Wall Nico Janssens Elliot Tapper |
| author_sort | Maria-Magdalena Balp |
| collection | DOAJ |
| description | Background & Aims: Data on the economic and humanistic burden of non-alcoholic steatohepatitis (NASH) are scarce. This study assessed the comparative burden of NASH, relative to a representative sample from the general population and a type 2 diabetes mellitus (T2DM) cohort, in terms of health-related quality of life, work productivity and activity impairment (WPAI), and healthcare resource use. Methods: Data across 5 European countries came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey. Outcomes included mental (MCS) and physical (PCS) component scores from the Short-Form (SF)-36v2, WPAI scores, self-reported physician diagnosis of sleep difficulties, anxiety, and depression, and healthcare resource use: healthcare professional visits, hospital visits, and emergency room visits in the previous 6 months. Bivariate and multivariable analyses were conducted for each outcome and comparative group. Results: After adjusting for matching criteria and covariates, patients with NASH (n = 184) reported significantly worse health-related quality of life, worse WPAI scores, and more healthcare resource use than the general population (n = 736) (MCS 39.22 vs. 45.16, PCS 42.84 vs. 47.76; overall work impairment 49.15% vs. 30.77%, healthcare professional visits 10.73 vs. 6.01, emergency room visits 0.57 vs. 0.22, hospitalizations 0.47 vs. 0.17, p ≪0.05 for all). Patients with NASH did not differ from patients with T2DM (n = 368) on PCS and WPAI scores, suggesting a similar impairment on work and daily activities, but did report significantly worse mental status (MCS 39.64 vs. 43.64, p ≪0.05) and more healthcare resource use than those with T2DM (healthcare professional visits 10.85 vs. 7.86, emergency room visits 0.65 vs. 0.23, hospitalizations 0.39 vs. 0.19, p ≪0.05 for all). Conclusions: These findings suggest that the burden of NASH may be underestimated, highlighting the unmet needs of patients with NASH. Lay summary: These findings show that patients with non-alcoholic steatohepatitis (NASH) experience a significant burden of illness, in terms of health-related quality of life, work productivity and activity impairment, and healthcare resource use. As there is currently no approved treatment for NASH, these findings highlight the unmet medical need of patients with NASH. Keywords: non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, type 2 diabetes, burden of illness |
| first_indexed | 2024-04-12T21:54:49Z |
| format | Article |
| id | doaj.art-2c470badbfe9413faa72f9b3bb0fe0ea |
| institution | Directory Open Access Journal |
| issn | 2589-5559 |
| language | English |
| last_indexed | 2024-04-12T21:54:49Z |
| publishDate | 2019-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHEP Reports |
| spelling | doaj.art-2c470badbfe9413faa72f9b3bb0fe0ea2022-12-22T03:15:21ZengElsevierJHEP Reports2589-55592019-09-0113154161The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes studyMaria-Magdalena Balp0Nancy Krieger1Raymond Przybysz2Nate Way3Jennifer Cai4Dion Zappe5Sarah Jane McKenna6Garth Wall7Nico Janssens8Elliot Tapper9Novartis Pharma AG, Basel, SwitzerlandNovartis Pharmaceuticals Corp., East Hanover, New Jersey, USNovartis Pharmaceuticals Corp., East Hanover, New Jersey, USHealth Outcomes Practice, Kantar Health, San Mateo, California, US; Corresponding author. Address: 1810 Gateway Drive, Suite 120, San Mateo, CA 94404; Tel.: +1 805 249 9036.Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USNovartis Pharmaceuticals Corp., East Hanover, New Jersey, USNovartis Business Services Centre, Dublin, IrelandNovartis Pharmaceuticals Corp., East Hanover, New Jersey, USNovartis Pharma AG, Basel, SwitzerlandUniversity of Michigan, Ann Arbor, Michigan, USBackground & Aims: Data on the economic and humanistic burden of non-alcoholic steatohepatitis (NASH) are scarce. This study assessed the comparative burden of NASH, relative to a representative sample from the general population and a type 2 diabetes mellitus (T2DM) cohort, in terms of health-related quality of life, work productivity and activity impairment (WPAI), and healthcare resource use. Methods: Data across 5 European countries came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey. Outcomes included mental (MCS) and physical (PCS) component scores from the Short-Form (SF)-36v2, WPAI scores, self-reported physician diagnosis of sleep difficulties, anxiety, and depression, and healthcare resource use: healthcare professional visits, hospital visits, and emergency room visits in the previous 6 months. Bivariate and multivariable analyses were conducted for each outcome and comparative group. Results: After adjusting for matching criteria and covariates, patients with NASH (n = 184) reported significantly worse health-related quality of life, worse WPAI scores, and more healthcare resource use than the general population (n = 736) (MCS 39.22 vs. 45.16, PCS 42.84 vs. 47.76; overall work impairment 49.15% vs. 30.77%, healthcare professional visits 10.73 vs. 6.01, emergency room visits 0.57 vs. 0.22, hospitalizations 0.47 vs. 0.17, p ≪0.05 for all). Patients with NASH did not differ from patients with T2DM (n = 368) on PCS and WPAI scores, suggesting a similar impairment on work and daily activities, but did report significantly worse mental status (MCS 39.64 vs. 43.64, p ≪0.05) and more healthcare resource use than those with T2DM (healthcare professional visits 10.85 vs. 7.86, emergency room visits 0.65 vs. 0.23, hospitalizations 0.39 vs. 0.19, p ≪0.05 for all). Conclusions: These findings suggest that the burden of NASH may be underestimated, highlighting the unmet needs of patients with NASH. Lay summary: These findings show that patients with non-alcoholic steatohepatitis (NASH) experience a significant burden of illness, in terms of health-related quality of life, work productivity and activity impairment, and healthcare resource use. As there is currently no approved treatment for NASH, these findings highlight the unmet medical need of patients with NASH. Keywords: non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, type 2 diabetes, burden of illnesshttp://www.sciencedirect.com/science/article/pii/S2589555919300576 |
| spellingShingle | Maria-Magdalena Balp Nancy Krieger Raymond Przybysz Nate Way Jennifer Cai Dion Zappe Sarah Jane McKenna Garth Wall Nico Janssens Elliot Tapper The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study JHEP Reports |
| title | The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study |
| title_full | The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study |
| title_fullStr | The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study |
| title_full_unstemmed | The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study |
| title_short | The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study |
| title_sort | burden of non alcoholic steatohepatitis nash among patients from europe a real world patient reported outcomes study |
| url | http://www.sciencedirect.com/science/article/pii/S2589555919300576 |
| work_keys_str_mv | AT mariamagdalenabalp theburdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT nancykrieger theburdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT raymondprzybysz theburdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT nateway theburdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT jennifercai theburdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT dionzappe theburdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT sarahjanemckenna theburdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT garthwall theburdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT nicojanssens theburdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT elliottapper theburdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT mariamagdalenabalp burdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT nancykrieger burdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT raymondprzybysz burdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT nateway burdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT jennifercai burdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT dionzappe burdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT sarahjanemckenna burdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT garthwall burdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT nicojanssens burdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy AT elliottapper burdenofnonalcoholicsteatohepatitisnashamongpatientsfromeuropearealworldpatientreportedoutcomesstudy |